Norbert Grzasko

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1305970/publications.pdf

Version: 2024-02-01

52 papers	1,638 citations	566801 15 h-index	288905 40 g-index
52 all docs	52 docs citations	52 times ranked	2501 citing authors

#	Article	IF	Citations
1	Common gene variants within 3â€²â€untranslated regions as modulators of multiple myeloma risk and survival. International Journal of Cancer, 2021, 148, 1887-1894.	2.3	3
2	Differential Function of a Novel Population of the CD19+CD24hiCD38hi Bregs in Psoriasis and Multiple Myeloma. Cells, 2021, 10, 411.	1.8	7
3	Expression quantitative trait loci of genes predicting outcome are associated with survival of multiple myeloma patients. International Journal of Cancer, 2021, 149, 327-336.	2.3	3
4	Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. Journal of Clinical Oncology, 2021, 39, 2430-2442.	0.8	53
5	Bendamustine-Based Regimens as Salvage Therapy in Refractory/Relapsed Multiple Myeloma Patients: A Retrospective Real-Life Analysis by the Polish Myeloma Group. Journal of Clinical Medicine, 2021, 10, 5504.	1.0	1
6	Cereblon (CRBN) gene polymorphisms predict clinical response and progression-free survival in relapsed/refractory multiple myeloma patients treated with lenalidomide: a pharmacogenetic study from the IMMEnSE consortium. Leukemia and Lymphoma, 2020, 61, 699-706.	0.6	3
7	Expression and Clinical Significance of Neuropilin-1 in Patients With Multiple Myeloma. Anticancer Research, 2020, 40, 5437-5443.	0.5	2
8	A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma. American Journal of Hematology, 2020, 95, 503-509.	2.0	11
9	Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients. Leukemia and Lymphoma, 2020, 61, 1885-1893.	0.6	3
10	Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients. Leukemia and Lymphoma, 2019, 60, 118-123.	0.6	23
11	18F-fluoro-ethyl-tyrosine (18F-FET) PET/CT as a potential new diagnostic tool in multiple myeloma: a preliminary study. Wspolczesna Onkologia, 2019, 23, 23-31.	0.7	9
12	Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma. Leukemia, 2019, 33, 2324-2330.	3.3	33
13	Ixazomib maintenance therapy in newly diagnosed multiple myeloma: An integrated analysis of four phase I/II studies. European Journal of Haematology, 2019, 102, 494-503.	1.1	11
14	All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. European Journal of Cancer, 2019, 106, 89-98.	1.3	25
15	Phase 2 study of allâ€oral ixazomib, cyclophosphamide and lowâ€dose dexamethasone for relapsed/refractory multiple myeloma. British Journal of Haematology, 2019, 184, 536-546.	1.2	16
16	Genetic polymorphisms in genes of class switch recombination and multiple myeloma risk and survival: an IMMEnSE study. Leukemia and Lymphoma, 2019, 60, 1803-1811.	0.6	11
17	The MP0250-CP201 Mirror Study: A Phase 2 Study Update of MP0250 Plus Bortezomib and Dexamethasone in Relapse/Refractory Multiple Myeloma (RRMM) Patients Previously Exposed to Proteasome Inhibitors and Immunomodulatory Drugs. Blood, 2019, 134, 1899-1899.	0.6	2
18	High efficacy and safety of VTD as an induction protocol in patients with newly diagnosed multiple myeloma eligible for high dose therapy and autologous stem cell transplantation: A report of the Polish Myeloma Study Group. Oncology Letters, 2019, 18, 5811-5820.	0.8	4

#	Article	IF	Citations
19	Wyzwania wczesnej diagnostyki szpiczaka plazmocytowego â€“ algorytm diagnostyczny. Acta Haematologica Polonica, 2019, 50, 121-129.	0.1	0
20	Diagnostyka gorÄ…czki u pacjentki z rozpoznaniem przewlekÅ‚ej biaÅ‚aczki limfocytowej. Acta Haematologica Polonica, 2019, 50, 174-179.	0.1	0
21	Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients. British Journal of Haematology, 2018, 180, 831-839.	1.2	41
22	The efficacy and safety of pomalidomide in relapsed/refractory multiple myeloma in a â€œrealâ€•worldâ€• study: Polish Myeloma Group experience. European Journal of Haematology, 2018, 101, 354-361.	1.1	13
23	The Prognostic Impact of t(14;16) in Multiple Myeloma: A Multicenter Retrospective Study of 213 Patients. Is It Time to Revise the Revised ISS?. Blood, 2018, 132, 4452-4452.	0.6	3
24	The Prognostic Impact of t(14;20) in Multiple Myeloma - a Multicenter Retrospective Study of 26 Patients. Blood, 2018, 132, 5600-5600.	0.6	0
25	MP0250 Combined with Bortezomib and Dexamethasone in Multiple Myeloma Patients Previoulsy Exposed to Proteasome Inhibitors and Immunomodulatory Drugs. Blood, 2018, 132, 1980-1980.	0.6	1
26	Nowe terapie w leczeniu szpiczaka z wysokim ryzykiem cytogenetycznym. Acta Haematologica Polonica, 2018, 49, 102-111.	0.1	0
27	Chromosome 1 amplification has similar prognostic value to del(17p13) and t(4;14)(p16;q32) in multiple myeloma patients: analysis of real-life data from the Polish Myeloma Study Group. Leukemia and Lymphoma, 2017, 58, 2089-2100.	0.6	12
28	Phase 2 study of tabalumab, a human antiâ€Bâ€•cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma. British Journal of Haematology, 2017, 176, 783-795.	1.2	39
29	Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs . placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1. Haematologica, 2017, 102, 1767-1775.	1.7	48
30	Identification of miRSNPs associated with the risk of multiple myeloma. International Journal of Cancer, 2017, 140, 526-534.	2.3	8
31	Comparative proteomic profiling of refractory/relapsed multiple myeloma reveals biomarkers involved in resistance to bortezomib-based therapy. Oncotarget, 2016, 7, 56726-56736.	0.8	58
32	Central nervous system involvement by multiple myeloma: A multiâ€•institutional retrospective study of 172 patients in daily clinical practice. American Journal of Hematology, 2016, 91, 575-580.	2.0	83
33	Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. New England Journal of Medicine, 2016, 374, 1621-1634.	13.9	861
34	DziesiÄ™ciolecie Polskiej Grupy Szpiczakowej â€“ historia i osiÄ…gniÄ™cia. Acta Haematologica Polonica, 2015, 46, 212-223.	0.1	0
35	Thalidomide can promote erythropoiesis by induction of STAT5 and repression of external pathway of apoptosis resulting in increased expression of GATA-1 transcription factor. Pharmacological Reports, 2015, 67, 1193-1200.	1.5	3
36	Therapyâ€•related peripheral neuropathy in multiple myeloma patients. Hematological Oncology, 2015, 33, 113-119.	0.8	63

#	Article	IF	Citations
37	Optimizing the Treatment of Patients WithÂMultiple Myeloma and Renal Impairment. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 187-198.	0.2	20
38	Case-adjusted bortezomib-based strategy in routine therapy of relapsed/refractory multiple myeloma shown to be highly effectiveâ€"A report by Polish Myeloma Study Group. Leukemia Research, 2014, 38, 788-794.	0.4	4
39	Dwu-, trzy- i czterolekowe schematy w leczeniu pierwszoliniowym szpiczaka plazmocytowego z uwzglÄ™dnieniem efektÃ³w terapii z zastosowaniem bortezomibu. Acta Haematologica Polonica, 2014, 45, 26-34.	0.1	0
40	A clinical comparison of the efficacy and safety of biosimilar G-CSF and originator G-CSF in haematopoietic stem cell mobilization. Pharmacological Reports, 2014, 66, 239-242.	1.5	29
41	Additional genetic abnormalities significantly worsen poor prognosis associated with 1q21 amplification in multiple myeloma patients. Hematological Oncology, 2013, 31, 41-48.	0.8	39
42	1q21 amplification with additional genetic abnormalities but not isolated 1q21 gain is a negative prognostic factor in newly diagnosed patients with multiple myeloma treated with thalidomide-based regimens. Leukemia and Lymphoma, 2012, 53, 2500-2503.	0.6	10
43	Thalidomide, dexamethasone and lovastatin with autologous stem cell transplantation as a salvage immunomodulatory therapy in patients with relapsed and refractory multiple myeloma. Annals of Hematology, 2011, 90, 1161-1166.	0.8	46
44	Impact of 1q21 Amplification Alone and in Combination with Other Genetic Abnormalities on Outcome in Multiple Myeloma Patients Treated with Thalidomide-Based Regimens. Blood, 2011, 118, 2874-2874.	0.6	1
45	Efficacy and Safety of Biosimilar G-CSF and Originator G-CSF for Haematopoietic Stem Cell Mobilisation: A Randomised Comparison. Blood, 2011, 118, 4392-4392.	0.6	0
46	The efficacy and safety of the low-thalidomide dose CTD (cyclophosphamide, thalidomide,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 387 Td Group. Leukemia Research, 2010, 34, 1330-1335.	0.4	14
47	Acute T Cell Lymphoblastic Leukemia in the Recipient of a Renal Transplant from a Donor with Malignant Lymphoma. Acta Haematologica, 2008, 119, 187-189.	0.7	3
48	Effective Therapy with Thalidomide/Lovastatin in a Patient with Primary Plasma Cell Leukemia. Clinical Leukemia, 2007, 1, 195-197.	0.2	0
49	Lovastatin and thalidomide have a combined effect on the rate of multiple myeloma cell apoptosis in short term cell cultures. European Journal of Clinical Pharmacology, 2006, 62, 325-329.	0.8	12
50	Stimulation of erythropoiesis by thalidomide in multiple myeloma patients: its influence on FasL, TRAIL and their receptors on erythroblasts. Haematologica, 2006, 91, 386-9.	1.7	7
51	Lovastatin and Thalidomide Have an Synergic Effect on the Rate of Multiple Myeloma Cell Apoptosis in Short Term Cell Cultures.. Blood, 2005, 106, 5121-5121.	0.6	0
52	Stimulation of Erythropoiesis by Thalidomide in Multiple Myeloma Patients: Its Influence on FasL, TRAIL and Their Receptors on Erythroblasts and Plasma Cells.. Blood, 2005, 106, 5120-5120.	0.6	0